1. Home
  2. CYTK vs ALGN Comparison

CYTK vs ALGN Comparison

Compare CYTK & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$76.84

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Logo Align Technology Inc.

ALGN

Align Technology Inc.

N/A

Current Price

$174.19

Market Cap

12.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CYTK
ALGN
Founded
1997
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
12.7B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
CYTK
ALGN
Price
$76.84
$174.19
Analyst Decision
Strong Buy
Buy
Analyst Count
19
12
Target Price
$89.26
$199.82
AVG Volume (30 Days)
1.7M
847.0K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.53
EPS
N/A
3.09
Revenue
$13,368,000.00
$387,126,000.00
Revenue This Year
$7.37
$5.78
Revenue Next Year
$310.19
$4.62
P/E Ratio
N/A
$57.10
Revenue Growth
N/A
23.95
52 Week Low
$34.60
$122.00
52 Week High
$88.31
$200.44

Technical Indicators

Market Signals
Indicator
CYTK
ALGN
Relative Strength Index (RSI) 45.54 49.38
Support Level $73.95 $164.70
Resistance Level $79.66 $180.17
Average True Range (ATR) 2.91 6.68
MACD -0.37 0.18
Stochastic Oscillator 33.77 37.47

Price Performance

Historical Comparison
CYTK
ALGN

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About ALGN Align Technology Inc.

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Share on Social Networks: